Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours

NCT05489211 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05489211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05489211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Recruiting
Start date
September 6, 2022
Completion date
October 1, 2027
Enrollment
454 (estimated)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, colorectal cancer, endometrial cancer, gastric cancer, metastatic castration-resistant prostate cancer, ovarian cancer, urothelial cancer